IL17A: Interleukin-17A
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity.
- Drugs that act on it: 11
- With a US drug page: 3
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Bimekizumab | Approved | Interleukin 17A inhibitor | Inhibitor | — |
| Ixekizumab | Approved | Interleukin 17A inhibitor | Inhibitor | — |
| Secukinumab | Approved | Interleukin 17A inhibitor | Inhibitor | — |
| Afasevikumab | — | Interleukin 17A inhibitor | Inhibitor | — |
| CJM-112 | — | Interleukin 17A binding agent | Binding agent | — |
| Izokibep | — | Interleukin 17A inhibitor | Inhibitor | — |
| M-1095 | — | Interleukin 17A inhibitor | Inhibitor | — |
| Perakizumab | — | Interleukin 17A inhibitor | Inhibitor | — |
| Remtolumab | — | Interleukin 17A inhibitor | Inhibitor | — |
| Tibulizumab | — | Interleukin 17A inhibitor | Inhibitor | — |
| Vunakizumab | — | Interleukin 17A inhibitor | Inhibitor | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associationsDrugs and mechanisms are from ChEMBL CHEMBL3390822 (CC BY-SA 3.0). Gene name, function (UniProt Q16552, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets